A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).
Inclusion Criteria: -
Exclusion Criteria: -
Setagaya-ku, 154-0004, Japan
Shibuya-ku, 151-0051, Japan
Shibuya-ku, 151-0053, Japan
Toshima-ku, 170-0002, Japan
Bratislava Mestská Časť Ružinov, 820 07, Slovakia
Liptovský Mikuláš, 031 23, Slovakia